Cipla
Cipla Limited (BSE: 500087, NSE: CIPLA) is a prominent Indian pharmaceutical company, best-known outside its home country for manufacturing low-cost anti-AIDS drugs for HIV-positive patients in developing countries. Founded by Khwaja Abdul Hamied as The Chemical, Industrial & Pharmaceutical Laboratories in 1935, Cipla makes drugs to treat cardiovascular disease, arthritis, diabetes, weight control, depression and many other health conditions, and its products are distributed in more than 180 countries worldwide.[2]
Cipla is also considerably well-known for its technological innovation and processes, and has been approved by regulatory bodies such as:
Food and Drug Administration (FDA), USA
Medicines and Healthcare products Regulatory Agency (MHRA), UK
Therapeutic Goods Administration (TGA), Australia
Medicines Control Council (MCC), South Africa
National Institute of Pharmacy (NIP), Hungary
Pharamaceutical Inspection Convention (PIC), Germany
World Health Organisation (WHO) Department of Health, Canada
State Institute for the Control of Drugs, Slovak Republic ANVISA, Brazil
[edit]